MediWound's $70m IPO at low end of target
This article was originally published in Clinica
Israel’s MediWound has priced its initial public offering, but the $70m total was at the low end of its expectations. The firm had been hoping to sell five million shares at $14-16 each, raising up to $80m in total, in fact had to settle for the bottom of this range. The underwriters also have the option to purchase up to 750,000 more shares at the same price, which could top up the grand total. The company began trading on the Nasdaq today under the ticker symbol MDWD. In spite of the disappointing total, the offering will be heartening to both MediWound and other start-ups considering taking a chance on the public market. So far this year, Clinica has recorded a total of 12 filings, and four, including MediWound, have succeeded in going public, bolstering hopes that the medtech IPO market is picking up.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.